Blog
Published September 12, 2024
The short answer is yes, by powering process automation with GenAI. It’s an approach that hasn’t received as much attention as other GenAI use cases within life sciences, but the results can be very powerful.
To illustrate its power, we’ll examine a case study on identifying debarred healthcare professionals (HCPs).
Why is it important to identify debarred HCPs?
Pharmaceutical companies are mandated to cease all forms of engagement with debarred healthcare professionals (HCPs) in the U.S.
Compliance entails identifying and…
Read Now
Blog
Published September 5, 2024
First, what does “omnichannel” mean in life sciences?
Omnichannel is a customer-centric strategy leveraging technology, data and analytics across functions to optimize cross-channel engagement.
So, why is it so hard to achieve effective customer engagement impact?
There are some companies that have achieved intended outcomes when deploying “Omnichannel” and embarking on a “digital transformation” – but many have found it much harder than expected.
The challenges are driven by three areas of misperception:
The simplistic view that omnichannel is a…
Read Now
Blog
Published August 16, 2024
Yesterday, CMS released the results of the first round of “negotiated” prices for the Inflation Reduction Act (IRA).1
The IRA is a historical landmark legislation for the pharmaceutical industry, and the results from these “negotiations” involving 10 of the top Medicare Part D drugs in terms of spend were eagerly awaited by many.
Immediately, both the Biden Administration and the Harris-Walz campaign commented on the public savings that these “negotiations” have generated, claiming this as a “beginning”.
“Medicare has reached…
Read Now
Blog
Published July 19, 2024
A recent bipartisan initiative by Senators Martin Heinrich, Mike Rounds, Marsha Blackburn and Todd Young urged the Centers for Medicare & Medicaid Services (CMS) to establish a formal payment pathway for algorithm-based health care services (ABHS). This move addresses the need for stable Medicare reimbursement for FDA-cleared AI and machine learning (ML) medical devices, which aid in diagnosis and treatment.
This initiative underscores AI’s transformative potential in healthcare, prompting Deepak Sahu, Managing Director at Trinity Life Sciences, and Michelle (武丹…
Read Now
Blog
Published June 13, 2024
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.
Understanding the Challenge
The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level…
Read Now
Blog
Published May 23, 2024
Executive Summary
The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market attractiveness. A few key developments announced or already implemented include:
The shift of the much-debated Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) to…
Read Now
Blog
Published May 17, 2024
Executive Summary
The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024.
Some key features of the reform plan include:
The creation of premiums for incentivizing the early introduction of new innovative therapies in Japan
The establishment of post-listing price adjustment scheme by average foreign price for specific imported drugs at the time of price revision
The simplification of the price maintenance premium (PMP) system so…
Read Now
Blog
Published April 30, 2024
Reliable forecast models are a cornerstone of any successful commercialization plan.
The inputs that drive those forecast models are critical.
From 2020 through 2022:
Only
1
in
10
products had performance aligned with forecasted expectations*
Nearly
60% underperformed their forecast expectations
More than
30% overperformed
Forecast models often rely on healthcare professional (HCP)-reported behavioral data.
Various subjective calibration factors are required to render the data usable, even after implementing robust market research design elements.
Data from primary market research (PMR)…
Read Now
Blog
Published April 22, 2024
Executive Summary
The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system.
The 2024 PLFSS emphasizes:
Drug access and cost containment, with a higher payback trigger aimed at reducing the government’s payback collections
Temporary reimbursement to ensure continuous treatment of patients with medicines benefitting from the early…
Read Now
Blog
Published April 5, 2024
Executive Summary
Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, as well as the implementation of time-limited reimbursement for specific drugs.
While the Canadian Drug Agency is set to advance Canada’s pharmaceutical system by standardizing…
Read Now
